Latest by Sean R. Hosein
Researchers with the New York Department of Health and Mental Hygiene have been trying to find ways to increase awareness of HCV and testing for it among people at high risk for this infection.
Scientists in France have recently noted that while the cascade of HIV care as it is currently envisaged is useful, it does not provide a complete picture of what is occurring in the continuum of care.
A small study adds to the growing body of evidence showing that early initiation of ART is effective and acceptable by people living with HIV.
In the Waves study, Stribild was judged to be statistically superior to an atazanavir-based regimen in women.
Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.
Factors such as increasing age, body mass index and having a high viral load prior to starting ART were associated with hormonal and metabolic abnormalities in HIV-positive women.
In the Aria study, Triumeq showed statistical superiority over an atazanavir-containing regimen at 48 weeks in HIV-positive women.
Analyzing many factors, researchers found that HIV infection was not a factor linked to an increased risk of falling in HIV-positive women.
An overivew of emerging themes in recent bacterial vaginosis research in HIV-positive women.
Analysis from the Women's Interagency HIV Study (WIHS) showed that women were "dissatisfied with current therapies" for bacterial vaginosis.